MAP2K7 and neoplasm: In both cell line-derived (CDX) and patient-derived xenograft (PDX) tumor models with KRASG12C mutation, D-1553 expressed anti-cancer activity as monotherapy and enhanced tumor growth inhibition or regression in combination with other targeted therapies (e.g., MEK inhibitor, SHP2 inhibitor) or chemotherapy.